Semaglutide
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight loss.
Clinical data | |
---|---|
Pronunciation | /sɛmˈæɡlʊtaɪd/ sem-AG-luu-tyde or /ˌsɛməˈɡluːtaɪd/ SEM-ə-GLOO-tyde |
Trade names | Ozempic, Rybelsus, Wegovy, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618008 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 89% |
Metabolism | Proteolysis |
Elimination half-life | 7 days |
Duration of action | 63.6 h |
Excretion | Urine and feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ECHA InfoCard | 100.219.541 |
Chemical and physical data | |
Formula | C187H291N45O59 |
Molar mass | 4113.641 g·mol−1 |
3D model (JSmol) | |
| |
|
Semaglutide is a glucagon-like peptide-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.
It was approved for medical use in the US in 2017. In 2021, it was the 90th most commonly prescribed medication in the United States, with more than 8 million prescriptions.